Truman Christine J, Goldberg Joseph F, Ghaemi S Nassir, Baldassano Claudia F, Wisniewski Stephen R, Dennehy Ellen B, Thase Michael E, Sachs Gary S
Finney Psychotherapy Associates, Norfolk, Va., USA.
J Clin Psychiatry. 2007 Oct;68(10):1472-9. doi: 10.4088/jcp.v68n1002.
Antidepressant safety and efficacy remain controversial for the treatment of bipolar depression. The present study utilized data from the National Institute of Mental Health Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) to examine the prevalence and clinical correlates of self-reported switch into mania/hypomania during antidepressant treatment.
Antidepressant treatment histories were examined from intake assessments for the first 500 subjects enrolled into the STEP-BD between November 1999 and November 2000. Affective switch was defined as a report of mania, hypomania, or mixed episodes within the first 12 weeks of having started an antidepressant. Demographic and clinical characteristics were compared for subjects with or without a history of acute switch during antidepressant treatment.
Among the 338 subjects with prior antidepressant treatment and complete data on switch event outcomes, 44% reported at least 1 such occurrence. Patients with a shorter duration of illness (odds ratio [OR] = 1.02, 95% CI = 1.01 to 1.04) and a history of multiple antidepressant trials (OR = 1.73, 95% CI = 1.38 to 2.16) were more likely to report a history of switch than other patients. A significantly increased risk for affective polarity switch was identified in patients who had ever switched to mania/hypomania while taking tricyclic antidepressants (OR = 7.80, 95% CI = 1.56 to 28.9), serotonin reuptake inhibitors (OR = 3.73, 95% CI = 1.98 to 7.05), or bupropion (OR = 4.28, 95% CI = 1.72 to 10.6). Switch was less common during treatment with electroconvulsive therapy or monoamine oxidase inhibitors than other antidepressants.
Antidepressants are associated with the potential risk for treatment-emergent mania or hypomania, particularly in bipolar patients with short illness duration, multiple past antidepressant trials, and past experience of switch with at least one antidepressant.
抗抑郁药治疗双相抑郁的安全性和有效性仍存在争议。本研究利用美国国立精神卫生研究所双相情感障碍系统治疗强化项目(STEP - BD)的数据,来研究在抗抑郁治疗期间自我报告转为躁狂/轻躁狂的患病率及其临床相关因素。
对1999年11月至2000年11月期间纳入STEP - BD的前500名受试者的入组评估中的抗抑郁治疗史进行了检查。情感转换被定义为在开始使用抗抑郁药的前12周内报告有躁狂、轻躁狂或混合发作。对有或没有抗抑郁治疗期间急性转换史的受试者的人口统计学和临床特征进行了比较。
在338名有既往抗抑郁治疗且有转换事件结局完整数据的受试者中,44%报告至少有1次此类情况发生。病程较短的患者(比值比[OR]=1.02,95%置信区间[CI]=1.01至1.04)和有多次抗抑郁试验史的患者(OR = 1.73,95% CI = 1.38至2.16)比其他患者更有可能报告有转换史。在服用三环类抗抑郁药、5-羟色胺再摄取抑制剂或安非他酮期间曾转为躁狂/轻躁狂的患者中,发现情感极性转换风险显著增加(OR分别为7.80,95% CI = 1.56至28.9;3.73,95% CI = 1.98至7.05;4.28,95% CI = 1.72至10.6)。与其他抗抑郁药相比,在接受电休克治疗或单胺氧化酶抑制剂治疗期间转换情况较少见。
抗抑郁药与治疗中出现躁狂或轻躁狂的潜在风险相关,尤其是在病程短、既往有多次抗抑郁试验以及既往至少有一次使用抗抑郁药后出现转换情况的双相情感障碍患者中。